跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
miR-150
首页
药物
miR-150
miR-150
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Purpose of hsa-miR-150
申请人: SHANGHAI BIOCHIP CO LTD
优先权: 2010
CN
Application of miR-150 and exosome loaded with miR-150 simulant to preparation of medicine for treating colorectal cancer
申请人: ZHONGSHAN HOSPITAL FUDAN UNIV
优先权: 2021
CN
Anti-leukemia small molecular compound targeting mir-150
申请人: SHANGHAI CLUSTER BIOTECH CO LTD
优先权: 2010
CN
MIR-150 FOR THE TREATMENT OF BLOOD DISORDERS
申请人: GEN HOSPITAL CORP
优先权: 2009
US
5 件公开
MiR-150 loaded mesoporous silicon nano-carrier and preparation method thereof
申请人: SHANGHAI 10TH PEOPLES HOSPITAL
优先权: 2021
CN
Application of LNA-anti-miR-150 in preparing drug for preventing or treating renal fibrosis
申请人: SHENGJING HOSPITAL CHINA MEDICAL UNIV
优先权: 2019
CN
Methods for treating subjects suffering from acute myeloid leukemia with FLT3 ligand-targeted miR-150 nanoparticles
申请人: UNIV CINCINNATI
优先权: 2017
US
2 件公开
Application of miR-150 inhibitor in preparation of medicine for activating adult myocardial cell reentry cell cycle
申请人: SHANGHAI EAST HOSPITAL TONGJI UNIV AFFILIATED EAST HOSPITAL
优先权: 2026
CN
药物
反馈